Teachers, aids, caregivers and parents, if you've a great Social Story, here's a chance to put it to music and share it with others.
Many of you already know, in addition to being stepdad to a terrific young man on the spectrum, I'm also a banjo player. Most of you also know, winters up here in Minnesota are looooong. :) So long in fact that, if you're a musician, you've got time on your hands to practice and do creative things. I was talking with some of my creative music friends the other day and found we all had a common interest in writing music to Social Stories.
"What a great idea" I thought. "We could write original tunes and record videos of us playing them to kids. Then, thanks to VCASMO, we could combine these videos with Powerpoints (visuals) of the best Social Stories."
Video of Music here -- Visual of Social Story here
"And I know the perfect outlet for these musical, Social Stories - The Education Library at Autism Hangout!!"
It's been proven time and again that music helps open up our kids. So why not put together "the best of" our community-prepared Social Stories with music so that all our special kids can benefit? I got so excited about the idea I couldn't stand it!
Now, we all know ANYone can write a good Social Story, but I wanted to open it up to all the parents, caregivers, teachers and para-aids out there that have some GREAT prepared Social Stories that they're successfully using right now. Ideally your Story is complete with visuals (i.e. Powerpoints or other scanable artwork). And if it rhymes, even better!
So I'd like to invite you to send me your best, successful Social Stories that we may consider putting them to music! I figger' it's worth a try at least. So here's my official "cattle call."
Please Send Me Files of "The Best Of" Your Successful Social Stories.
I've got musician friends standing by waiting to be a part of this. Ideally, once the music is prepared, I can videotape the actual musical artist singing the Social Story to a bunch of kids (and place it next to the prepared visuals in the VCASMO format now being used in the Education Library). You can make 'em full-screen, you know. THAT will be awesome!!
I can't promise we'll use them all, but for the ones we do, I'll certainly give credit where it's due. And if I can figger out a way that everyone gets paid a little bit for their work, that would be great, too. But the fee has to be low enough that most folks and kids can take advantage of this incredible resource. I'm really excited about this! I hope you are as well!
Thanks again, everyone... for being a part of Autism Hangout!
Craig Evans, Founder - Autism Hangout
|< Prev||Next >|
Pfizer's Ibrance drug slows progression of breast cancer
By Deena Beasley CHICAGO (Reuters) - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance and AstraZeneca Plc's Faslodex (fulvestrant), a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened. The trial, presented in Chicago at a meeting of the American Society of Clinical Oncology, enrolled 521 patients whose breast cancer was classified as estrogen-receptor positive, human epidermal growth factor receptor 2-negative.
Study sees benefit from more extensive breast cancer surgery
CHICAGO (AP) — Having a little extra tissue taken off during breast cancer surgery greatly lowers the risk that some cancer will be left behind and require a second operation, according to a new study that could change care for more than 100,000 women in the United States alone each year.
New treatments may prolong health after breast cancer
Promising advances in research could mean longer, healthier lives for women with breast cancer, the number one cancer in women worldwide, experts said Saturday at a major US cancer conference. A new targeted therapy that appears to double the amount of time cancer can be held in check, a drug that offers more women a chance at healthy lives post-diagnosis and a surgical option to remove extra tissue in order to reduce the likelihood of cancer's return were among the findings presented at the American Society of Clinical Oncology annual meeting in Chicago. The targeted drug, palbociclib, is made by Pfizer and was granted accelerated approval by the US Food and Drug Administration earlier this year for use in women with the most common form of advanced breast cancer, known as estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-).
4 Traps to Avoid When You're Filled With Anxiety
When we're slipping on anxiety's slopes, it's usually not pretty.We rant. We rave. We make blanket statements on the condition of our lives.When under pressure, inaccurate self-judgments are likely to creep in. We forget to factor in that we're overworked, tired or just plain depleted. We lose sight that we're resilient, and quite capable of...
Former quadriplegic runs, walks to show others they can
LOS ANGELES (AP) — The worst day of Aaron Baker's life wasn't when the then-20-year-old professional motocross racer crashed his bike one spring day in 1999, flew over the handlebars and hit the ground head-first, paralyzing him from the next down.
Eisai drug extends survival in patients with rare cancers
A drug made by Japan's Eisai Co that was originally derived from sea sponges helped extend lives of patients with soft-tissue cancers known as sarcomas by two months, a significant advance for these rare cancers with few treatment options, Belgian researchers said on Saturday. The researchers studied the drug, known as eribulin, in 452 patients with two forms of sarcomas - leiomyosarcoma, which starts in smooth muscles, and adipocytic sarcoma, which starts in fat tissue. "For a disease where such few treatment options exist, a two month improvement in survival is significant," said Dr. Patrick Schoffski, a medical oncologist at University Hospitals Leuven in Belgium, who presented the findings at the American Society of Clinical Oncology meeting on Saturday.
J&J multiple myeloma drug offers hope after others stop working: study
An experimental biotech drug being developed by Johnson & Johnson may offer hope to multiple myeloma patients who have run out of options, according to data from a midstage study released at a cancer meeting on Saturday. J&J plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab to treat the blood cancer. The drug received breakthrough designation from the U.S. Food and Drug Administration, which can help speed the approval process.
New research shows immunotherapy targeting several cancers
Immunotherapy, which has shown remarkable success against advanced melanoma skin cancers, is now being used to target other cancers that are tough to treat. The results of several clinical trials were presented on the opening day of the American Society of Clinical Oncology's (ASCO) annual conference in Chicago on Friday. In some cases, immunotherapy has been shown to completely eradicate cancer.
Drug boosts long-term survival after breast cancer: study
After a diagnosis of localized breast cancer, women are often prescribed tamoxifen for five years to help prevent a recurrence, but researchers said Saturday another drug, anastrazole, may work better. The federally funded phase III study involved more than 3,100 postmenopausal women with a kind of breast cancer known as ductal carcinoma in situ, which was treated by removing the cancerous lump followed by a radiation regimen. Some women were then randomly assigned to receive tamoxifen and others anastrazole.
U.N. warns of coming hunger in North Korea
By Tom Miles GENEVA (Reuters) - A drought in North Korea could lead to huge food shortages this year, the top U.N. official in the country told Reuters in an interview. Rainfall in 2014, the lowest in records going back 30 years, was 40-60 percent below 2013 levels, and reservoirs are very low, said Ghulam Isaczai, the U.N. resident coordinator.